REVIEW

Mesenchymal stem cells in progression and treatment of cancers

  • Qingguo ZHAO ,
  • Fei LIU
Expand
  • Institute for Regenerative Medicine at Scott & White, MCMD, Texas A&M Health Science Center, Temple, TX 76502, USA

Received date: 31 Mar 2014

Accepted date: 14 Apr 2014

Published date: 24 Jun 2014

Copyright

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg

Abstract

Mesenchymal stem or stromal cells (MSCs) from bone marrow or local tissues are recruited to stroma of almost all types of cancers during initiation and/or progression of cancer. The recruited MSCs and their derivative cancer-associated fibroblasts interact with cancer cells to promote stemness, invasion and metastasis of cancer cells. Targeting these cancer-recruited MSCs and/or the interaction between MSCs and cancer cells are promising strategies to improve cancer therapy. On the other hand, the unique tumor-homing capacity of MSCs makes them a promising vehicle to deliver various anti-cancer agents. This review summarized the recent advancement of our understanding on the interaction between MSCs and cancer cells, as well as the potential of MSCs for cancer therapy.

Cite this article

Qingguo ZHAO , Fei LIU . Mesenchymal stem cells in progression and treatment of cancers[J]. Frontiers in Biology, 2014 , 9(3) : 186 -194 . DOI: 10.1007/s11515-014-1306-2

1
BolontradeM F, SgangaL, PiaggioE, VialeD L, SorrentinoM A, RobinsonA, SevleverG, GarcíaM G, MazzoliniG, PodhajcerO L (2012). A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus. Stem Cells Dev, 21(14): 2689–2702

DOI PMID

2
BrunoS, CollinoF, DeregibusM C, GrangeC, TettaC, CamussiG (2013). Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev, 22(5): 758–771

DOI PMID

3
CarreroR, CerradaI, LledóE, DopazoJ, García-GarcíaF, RubioM P, TriguerosC, DorronsoroA, Ruiz-SauriA, MonteroJ A, SepúlvedaP (2012). IL1β induces mesenchymal stem cells migration and leucocyte chemotaxis through NF-κB. Stem Cell Rev, 8(3): 905–916

DOI PMID

4
CastletonA, DeyA, BeatonB, PatelB, AucherA, DavisD M, FieldingA K (2014). Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood, 123(9): 1327–1335

DOI PMID

5
CavarrettaI T, AltanerovaV, MatuskovaM, KucerovaL, CuligZ, AltanerC (2010). Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther, 18(1): 223–231

DOI PMID

6
ChaturvediP, GilkesD M, WongC C, LuoW, ZhangH, WeiH, TakanoN, SchitoL, LevchenkoA, SemenzaG L, and the Kshitiz (2013). Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest, 123(1): 189–205

PMID

7
ChenM Y, LieP C, LiZ L, WeiX (2009). Endothelial differentiation of Wharton’s jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. Exp Hematol, 37(5): 629–640

DOI PMID

8
De BoeckA, PauwelsP, HensenK, RummensJ L, WestbroekW, HendrixA, MaynardD, DenysH, LambeinK, BraemsG, GespachC, BrackeM, De WeverO (2013). Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut, 62(4): 550–560

DOI PMID

9
de PeppoG M, Marcos-CamposI, KahlerD J, AlsalmanD, ShangL, Vunjak-NovakovicG, MaroltD (2013). Engineering bone tissue substitutes from human induced pluripotent stem cells. Proc Natl Acad Sci USA, 110(21): 8680–8685

DOI PMID

10
Di StasiA, TeyS K, DottiG, FujitaY, Kennedy-NasserA, MartinezC, StraathofK, LiuE, DurettA G, GrilleyB, LiuH, CruzC R, SavoldoB, GeeA P, SchindlerJ, KranceR A, HeslopH E, SpencerD M, RooneyC M, BrennerM K (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med, 365(18): 1673–1683

DOI PMID

11
DuchiS, SotgiuG, LucarelliE, BallestriM, DozzaB, SantiS, GuerriniA, DambruosoP, GianniniS, DonatiD, FerroniC, VarchiG (2013). Mesenchymal stem cells as delivery vehicle of porphyrin loaded nanoparticles: effective photoinduced in vitro killing of osteosarcoma. J Control Release, 168(2): 225–237

DOI PMID

12
DvorakH F (1986). Tumors: wounds that do not heal.Similarities between tumor stroma generation and wound healing. N Engl J Med, 315(26): 1650–1659

DOI PMID

13
El-HaibiC P, BellG W, ZhangJ, CollmannA Y, WoodD, ScherberC M, CsizmadiaE, MarianiO, ZhuC, CampagneA, TonerM, BhatiaS N, IrimiaD, Vincent-SalomonA, KarnoubA E (2012). Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci USA, 109(43): 17460–17465

DOI PMID

14
ErlerJ T, BennewithK L, CoxT R, LangG, BirdD, KoongA, LeQ T, GiacciaA J (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell, 15(1): 35–44

DOI PMID

15
García-CastroJ, AlemanyR, CascallóM, Martínez-QuintanillaJ, ArrieroM M, LassalettaA, MaderoL, RamírezM (2010). Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther, 17(7): 476–483

DOI PMID

16
GoldenbergD M, GoldD V, LooM, LiuD, ChangC H, JaffeE S (2013). Horizontal transmission of malignancy: in-vivo fusion of human lymphomas with hamster stroma produces tumors retaining human genes and lymphoid pathology. PLoS ONE, 8(2): e55324

DOI PMID

17
GrisendiG, BussolariR, CafarelliL, PetakI, RasiniV, VeronesiE, De SantisG, SpanoC, TagliazzucchiM, Barti-JuhaszH, ScarabelliL, BambiF, FrassoldatiA, RossiG, CasaliC, MorandiU, HorwitzE M, PaolucciP, ConteP, DominiciM (2010). Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res, 70(9): 3718–3729

DOI PMID

18
HoI A, TohH C, NgW H, TeoY L, GuoC M, HuiK M, LamP Y (2013). Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells, 31(1): 146–155

DOI PMID

19
HongH S, LeeJ, LeeE, KwonY S, LeeE, AhnW, JiangM H, KimJ C, SonY (2009). A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells. Nat Med, 15(4): 425–435

DOI PMID

20
HoughtonJ, StoicovC, NomuraS, RogersA B, CarlsonJ, LiH, CaiX, FoxJ G, GoldenringJ R, WangT C (2004). Gastric cancer originating from bone marrow-derived cells. Science, 306(5701): 1568–1571

DOI PMID

21
IpJ E, WuY, HuangJ, ZhangL, PrattR E, DzauV J (2007). Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell, 18(8): 2873–2882

DOI PMID

22
JacobsenB M, HarrellJ C, JedlickaP, BorgesV F, Varella-GarciaM, HorwitzK B (2006). Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. Cancer Res, 66(16): 8274–8279

DOI PMID

23
JohannP D, VaeglerM, GiesekeF, MangP, Armeanu-EbingerS, KlubaT, HandgretingerR, MüllerI (2010). Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity. BMC Cancer, 10(1): 501

DOI PMID

24
JungY, KimJ K, ShiozawaY, WangJ, MishraA, JosephJ, BerryJ E, McGeeS, LeeE, SunH, WangJ, JinT, ZhangH, DaiJ, KrebsbachP H, KellerE T, PientaK J, TaichmanR S (2013). Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun, 4: 1795

DOI PMID

25
KarnoubA E, DashA B, VoA P, SullivanA, BrooksM W, BellG W, RichardsonA L, PolyakK, TuboR, WeinbergR A (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449(7162): 557–563

DOI PMID

26
KhakooA Y, PatiS, AndersonS A, ReidW, ElshalM F, RoviraI I, NguyenA T, MalideD, CombsC A, HallG, ZhangJ, RaffeldM, RogersT B, Stetler-StevensonW, FrankJ A, ReitzM, FinkelT (2006). Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med, 203(5): 1235–1247

DOI PMID

27
KiddS, CaldwellL, DietrichM, SamudioI, SpaethE L, WatsonK, ShiY, AbbruzzeseJ, KonoplevaM, AndreeffM, MariniF C (2010). Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy, 12(5): 615–625

DOI PMID

28
KimS W, KimS J, ParkS H, YangH G, KangM C, ChoiY W, KimS M, JeunS S, SungY C (2013). Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK. Clin Cancer Res, 19(2): 415–427

DOI PMID

29
KinnairdT, StabileE, BurnettM S, LeeC W, BarrS, FuchsS, EpsteinS E (2004). Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res, 94(5): 678–685

DOI PMID

30
KitadaiY, SasakiT, KuwaiT, NakamuraT, BucanaC D, HamiltonS R, FidlerI J (2006). Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer, 119(11): 2567–2574

DOI PMID

31
Kolluri,K.K., Laurent,G.J., and Janes,S.M. (2013). Mesenchymal stem cells as vectors for lung cancer therapy. Respiration; international review of thoracic diseases85, 443–451.

32
KomlevV S, MastrogiacomoM, PeyrinF, CanceddaR, RustichelliF (2009). X-ray synchrotron radiation pseudo-holotomography as a new imaging technique to investigate angio- and microvasculogenesis with no usage of contrast agents. Tissue Eng Part C Methods, 15(3): 425–430

DOI PMID

33
KramanM, BambroughP J, ArnoldJ N, RobertsE W, MagieraL, JonesJ O, GopinathanA, TuvesonD A, FearonD T (2010). Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science, 330(6005): 827–830

DOI PMID

34
KrausgrillB, VantlerM, BurstV, RathsM, HalbachM, FrankK, SchynkowskiS, SchenkK, HeschelerJ, RosenkranzS, Müller-EhmsenJ (2009). Influence of cell treatment with PDGF-BB and reperfusion on cardiac persistence of mononuclear and mesenchymal bone marrow cells after transplantation into acute myocardial infarction in rats. Cell Transplant, 18(8): 847–853

DOI PMID

35
KucerovaL, AltanerovaV, MatuskovaM, TyciakovaS, AltanerC (2007). Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res, 67(13): 6304–6313

DOI PMID

36
KucerovaL, MatuskovaM, PastorakovaA, TyciakovaS, JakubikovaJ, BohovicR, AltanerovaV, AltanerC (2008). Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med, 10(10): 1071–1082

DOI PMID

37
LarsonB L, YlostaloJ, LeeR H, GregoryC, ProckopD J (2010). Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells. Tissue Eng Part A, 16(11): 3385–3394

DOI PMID

38
LazovaR, LabergeG S, DuvallE, SpoelstraN, KlumpV, SznolM, CooperD, SpritzR A, ChangJ T, PawelekJ M (2013). A melanoma brain metastasis with a donor-patient hybrid genome following bone marrow transplantation: first evidence for fusion in human cancer. PLoS ONE, 8(6): e66731

DOI PMID

39
LeeR H, PulinA A, SeoM J, KotaD J, YlostaloJ, LarsonB L, Semprun-PrietoL, DelafontaineP, ProckopD J (2009a). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5(1): 54–63

DOI PMID

40
LeeR H, SeoM J, PulinA A, GregoryC A, YlostaloJ, ProckopD J (2009b). The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood, 113(4): 816–826

DOI PMID

41
LeeR H, YoonN, ReneauJ C, ProckopD J (2012). Preactivation of human MSCs with TNF-α enhances tumor-suppressive activity. Cell Stem Cell, 11(6): 825–835

DOI PMID

42
LesleyJ, GálI, MahoneyD J, CordellM R, RuggM S, HymanR, DayA J, MikeczK (2004). TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J Biol Chem, 279(24): 25745–25754

DOI PMID

43
LiH J, ReinhardtF, HerschmanH R, WeinbergR A (2012). Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov, 2(9): 840–855

DOI PMID

44
LinR, MaH, DingZ, ShiW, QianW, SongJ, HouX (2013). Bone marrow-derived mesenchymal stem cells favor the immunosuppressive T cells skewing in a Helicobacter pylori model of gastric cancer. Stem Cells Dev, 22(21): 2836–2848

DOI PMID

45
LiuS, GinestierC, OuS J, ClouthierS G, PatelS H, MonvilleF, KorkayaH, HeathA, DutcherJ, KleerC G, JungY, DontuG, TaichmanR, WichaM S (2011a). Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res, 71(2): 614–624

DOI PMID

46
LiuY, HanZ P, ZhangS S, JingY Y, BuX X, WangC Y, SunK, JiangG C, ZhaoX, LiR, GaoL, ZhaoQ D, WuM C, WeiL X (2011b). Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J Biol Chem, 286(28): 25007–25015

DOI PMID

47
LoebingerM R, EddaoudiA, DaviesD, JanesS M (2009). Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res, 69(10): 4134–4142

DOI PMID

48
LoebingerM R, JanesS M (2010). Stem cells as vectors for antitumour therapy. Thorax, 65(4): 362–369

DOI PMID

49
LuY R, YuanY, WangX J, WeiL L, ChenY N, CongC, LiS F, LongD, TanW D, MaoY Q, ZhangJ, LiY P, ChengJ Q (2008). The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther, 7(2): 245–251

DOI PMID

50
MaderE K, MaeyamaY, LinY, ButlerG W, RussellH M, GalanisE, RussellS J, DietzA B, PengK W (2009). Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res, 15(23): 7246–7255

DOI PMID

51
Martinez-QuintanillaJ, BhereD, HeidariP, HeD, MahmoodU, ShahK (2013). Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells, 31(8): 1706–1714

DOI PMID

52
MarxJ (2008). Cancer biology.All in the stroma: cancer’s Cosa Nostra. Science, 320(5872): 38–41

DOI PMID

53
MatuskovaM, HlubinovaK, PastorakovaA, HunakovaL, AltanerovaV, AltanerC, KucerovaL (2010). HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett, 290(1): 58–67

DOI PMID

54
MiZ, BhattacharyaS D, KimV M, GuoH, TalbotL J, KuoP C (2011). Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis, 32(4): 477–487

DOI PMID

55
MiZ, GuoH, RussellM B, LiuY, SullengerB A, KuoP C (2009). RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther, 17(1): 153–161

DOI PMID

56
MishraP J, MishraP J, HumeniukR, MedinaD J, AlexeG, MesirovJ P, GanesanS, GlodJ W, BanerjeeD (2008). Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res, 68(11): 4331–4339

DOI PMID

57
NasefA, MathieuN, ChapelA, FrickJ, FrançoisS, MazurierC, BoutarfaA, BouchetS, GorinN C, ThierryD, FouillardL (2007). Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation, 84(2): 231–237

DOI PMID

58
PatelS A, MeyerJ R, GrecoS J, CorcoranK E, BryanM, RameshwarP (2010). Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol, 184(10): 5885–5894

DOI PMID

59
PeinadoH, AlečkovićM, LavotshkinS, MateiI, Costa-SilvaB, Moreno-BuenoG, Hergueta-RedondoM, WilliamsC, García-SantosG, GhajarC, Nitadori-HoshinoA, HoffmanC, BadalK, GarciaB A, CallahanM K, YuanJ, MartinsV R, SkogJ, KaplanR N, BradyM S, WolchokJ D, ChapmanP B, KangY, BrombergJ, LydenD (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med, 18(6): 883–891

DOI PMID

60
PeterM E (2009). Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle, 8(6): 843–852

DOI PMID

61
QiaoL, XuZ L, ZhaoT J, YeL H, ZhangX D (2008). Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett, 269(1): 67–77

DOI PMID

62
QuanteM, TuS P, TomitaH, GondaT, WangS S, TakashiS, BaikG H, ShibataW, DipreteB, BetzK S, FriedmanR, VarroA, TyckoB, WangT C (2011). Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell, 19(2): 257–272

DOI PMID

63
RappaG, MercapideJ, LoricoA (2012). Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity. Am J Pathol, 180(6): 2504–2515

DOI PMID

64
RenC, KumarS, ChandaD, ChenJ, MountzJ D, PonnazhaganS (2008a). Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells, 26(9): 2332–2338

DOI PMID

65
RenC, KumarS, ChandaD, KallmanL, ChenJ, MountzJ D, PonnazhaganS (2008b). Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther, 15(21): 1446–1453

DOI PMID

66
SageE K, KolluriK K, McNultyK, LourencoS D, KalberT L, OrdidgeK L, DaviesD, Gary LeeY C, GiangrecoA, JanesS M (2014). Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma. Thorax,

DOI PMID

67
SánchezL, Gutierrez-ArandaI, LigeroG, RubioR, Muñoz-LópezM, García-PérezJ L, RamosV, RealP J, BuenoC, RodríguezR, DelgadoM, MenendezP (2011). Enrichment of human ESC-derived multipotent mesenchymal stem cells with immunosuppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease. Stem Cells, 29(2): 251–262

DOI PMID

68
SasportasL S, KasmiehR, WakimotoH, HingtgenS, van de WaterJ A, MohapatraG, FigueiredoJ L, MartuzaR L, WeisslederR, ShahK (2009). Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA, 106(12): 4822–4827

DOI PMID

69
SeoK W, LeeH W, OhY I, AhnJ O, KohY R, OhS H, KangS K, YounH Y (2011a). Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model. Cytotherapy, 13(8): 944–955

DOI PMID

70
SeoS H, KimK S, ParkS H, SuhY S, KimS J, JeunS S, SungY C (2011b). The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther, 18(5): 488–495

DOI PMID

71
ShangguanL, TiX, KrauseU, HaiB, ZhaoY, YangZ, LiuF (2012). Inhibition of TGF-β/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem Cells, 30(12): 2810–2819

DOI PMID

72
ShimodaM, MellodyK T, OrimoA (2010). Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol, 21(1): 19–25

DOI PMID

73
ShinagawaK, KitadaiY, TanakaM, SumidaT, OnoyamaM, OhnishiM, OharaE, HigashiY, TanakaS, YasuiW, ChayamaK (2013). Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer. Int J Cancer, 132(4): 813–823

DOI PMID

74
SongC, LiG (2011). CXCR4 and matrix metalloproteinase-2 are involved in mesenchymal stromal cell homing and engraftment to tumors. Cytotherapy, 13(5): 549–561

DOI PMID

75
SpaethE L, LabaffA M, TooleB P, KloppA, AndreeffM, MariniF C (2013). Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Res, 73(17): 5347–5359

DOI PMID

76
StroncekD, BerlyneD, FoxB, GeeA, HeimfeldS, LindbladR, LoperK, McKennaD Jr, RooneyC, SabatinoM, WagnerE, WhitesideT, WoodD, Heath-MondoroT (2010). Developments in clinical cell therapy. Cytotherapy, 12(3): 425–428

DOI PMID

77
SuzukiK, SunR, OriguchiM, KanehiraM, TakahataT, ItohJ, UmezawaA, KijimaH, FukudaS, SaijoY (2011). Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med, 17(7-8): 579–587

DOI PMID

78
TokarE J, DiwanB A, WaalkesM P (2010). Arsenic exposure transforms human epithelial stem/progenitor cells into a cancer stem-like phenotype. Environ Health Perspect, 118(1): 108–115

PMID

79
Toledano FurmanN E, Lupu-HaberY, BronshteinT, KanetiL, LetkoN, WeinsteinE, BaruchL, MachlufM (2013). Reconstructed stem cell nanoghosts: a natural tumor targeting platform. Nano Lett, 13(7): 3248–3255

DOI PMID

80
UchiboriR, OkadaT, ItoT, UrabeM, MizukamiH, KumeA, OzawaK (2009). Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med, 11(5): 373–381

DOI PMID

81
VarnatF, DuquetA, MalerbaM, ZbindenM, MasC, GervazP, Ruiz i AltabaA (2009). Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med, 1(6-7): 338–351

DOI PMID

82
ViswanathanS, KeatingA, DeansR, HemattiP, ProckopD, StroncekD F, StaceyG, WeissD J, MasonC, RaoM S (2014). Soliciting Strategies for Developing Cell-Based Reference Materials to Advance MSC Research and Clinical Translation. Stem Cells Dev: 140310064908006

DOI PMID

83
WangM L, PanC M, ChiouS H, ChenW H, ChangH Y, LeeO K, HsuH S, WuC W (2012). Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect. Cancer Res, 72(22): 6051–6064

DOI PMID

84
WuS, JuG Q, DuT, ZhuY J, LiuG H (2013). Microvesicles derived from human umbilical cord Wharton’s jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo. PLoS ONE, 8(4): e61366

DOI PMID

85
WuY, ZhouB P (2010). Snail: More than EMT. Cell Adhes Migr, 4(2): 199–203

DOI PMID

86
XinH, KanehiraM, MizuguchiH, HayakawaT, KikuchiT, NukiwaT, SaijoY (2007). Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells, 25(7): 1618–1626

DOI PMID

87
XuM H, GaoX, LuoD, ZhouX D, XiongW, LiuG X (2014). EMT and acquisition of stem cell-like properties are involved in spontaneous formation of tumorigenic hybrids between lung cancer and bone marrow-derived mesenchymal stem cells. PLoS ONE, 9(2): e87893

DOI PMID

88
XuS, MenuE, De BeckerA, Van CampB, VanderkerkenK, Van RietI (2012). Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells, 30(2): 266–279

DOI PMID

Outlines

/